TY - JOUR
T1 - Stimuli-responsive theranostic system
T2 - A promising approach for augmented multimodal imaging and efficient drug release
AU - Demiral, Ayşegül
AU - Goralı, S. İrem
AU - Yılmaz, Hülya
AU - Verimli, Nihan
AU - Çulha, Mustafa
AU - Erdem, S. Sibel
N1 - Funding Information:
The study described in this paper was supported by a grant from the Scientific and Technological Research Council of Turkey, TÜBİTAK with grant number 119S219.
Funding Information:
We would like to thank the SABITA administration for its support. We also thank Assist. Prof. Bilgesu Onur Sucu for her assistance in acquiring LC-MS data. The study described in this paper was supported by a grant from the Scientific and Technological Research Council of Turkey, TÜBİTAK with grant number 119S219.
Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/8
Y1 - 2022/8
N2 - Destruction of drug resistant and invisible micro-tumors requires innovative screening and treatment modalities. Theranostic nanosystems offering multimodal imaging and therapy are attractive platforms with potential to make micro-tumors visible to clinicians. Gold nanoparticles (AuNPs) are intrinsic theranostic agents and act as fluorescence quenchers. They can be easily transformed to multimodal imaging and combination therapy agents by combining them with various adjuvant therapies such as photodynamic therapy. In this study, we developed a highly specific, hybrid theranostic agent that is only activated when it meets with its stimuli at the site of interest. Surface-coated AuNPs were modified with Cathepsin B cleavable peptide (stimuli responsive linker) and Verteporfin (photosensitizer and fluorescence imaging agent). Unless the theranostic system meets with the internal stimuli in tumor cells, fluorescence is quenched due to AuNP-Verteporfin and Verteporfin-Verteporfin interactions. Following cellular internalization of the theranostic agent, fluorescence is gained by Cathepsin B cleavage and phototoxicity is initiated by light. The system was efficiently internalized by SKOV-3 cells and demonstrated high specificity towards its stimuli. In comparison to Verteporfin, ∼14-fold fluorescence increase, 81% fluorescence recovery and comparable toxicity were achieved. The system is a promising candidate for multimodal imaging and dual treatment to destroy the micro-tumors.
AB - Destruction of drug resistant and invisible micro-tumors requires innovative screening and treatment modalities. Theranostic nanosystems offering multimodal imaging and therapy are attractive platforms with potential to make micro-tumors visible to clinicians. Gold nanoparticles (AuNPs) are intrinsic theranostic agents and act as fluorescence quenchers. They can be easily transformed to multimodal imaging and combination therapy agents by combining them with various adjuvant therapies such as photodynamic therapy. In this study, we developed a highly specific, hybrid theranostic agent that is only activated when it meets with its stimuli at the site of interest. Surface-coated AuNPs were modified with Cathepsin B cleavable peptide (stimuli responsive linker) and Verteporfin (photosensitizer and fluorescence imaging agent). Unless the theranostic system meets with the internal stimuli in tumor cells, fluorescence is quenched due to AuNP-Verteporfin and Verteporfin-Verteporfin interactions. Following cellular internalization of the theranostic agent, fluorescence is gained by Cathepsin B cleavage and phototoxicity is initiated by light. The system was efficiently internalized by SKOV-3 cells and demonstrated high specificity towards its stimuli. In comparison to Verteporfin, ∼14-fold fluorescence increase, 81% fluorescence recovery and comparable toxicity were achieved. The system is a promising candidate for multimodal imaging and dual treatment to destroy the micro-tumors.
KW - Cathepsin B
KW - Fluorescence imaging
KW - Fluorescence quenching
KW - Gold nanoparticle
KW - Hybrid theranostic agent
KW - Multimodal imaging
KW - Near-IR fluorescent dye
KW - Photodynamic therapy
KW - Verteporfin
UR - http://www.scopus.com/inward/record.url?scp=85131749341&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131749341&partnerID=8YFLogxK
U2 - 10.1016/j.ejpb.2022.05.021
DO - 10.1016/j.ejpb.2022.05.021
M3 - Article
C2 - 35671914
AN - SCOPUS:85131749341
SN - 0939-6411
VL - 177
SP - 9
EP - 23
JO - European Journal of Pharmaceutics and Biopharmaceutics
JF - European Journal of Pharmaceutics and Biopharmaceutics
ER -